Would you offer TPO-RAs to a steroid-refractory chronic ITP patient with history of stroke?  

Is the thrombotic risk associated with TPO-RAs only relevant to VTE or does it also apply to arterial thromboses and stroke? Can the risk be mitigated with appropriate targeting of platelet count?

What platelet count would you target to allow for stroke-directed anti-platelet or anticoagulation therapy?